Large population studies from the United States and Taiwan have reported that the use of PPARγ agonists reduced the risk of COPD exacerbation29,30; likewise, PPARγ agonists also decreased the risk of exacerbation in patients with asthma31. The gene discussed is PPARG; the disease is chronic obstructive pulmonary disease.